Core Insights - Cogent Biosciences is poised for significant advancements in 2026, focusing on the commercialization of bezuclastinib and expanding its pipeline of therapies for genetically defined diseases [2][6][11] Milestones and Developments - In 2025, Cogent achieved positive results from pivotal trials of bezuclastinib for GIST and Systemic Mastocytosis, submitted its first NDA for NonAdvSM, and entered 2026 with approximately $900 million in cash [2][6] - The company plans to launch bezuclastinib in the second half of 2026, with NDA submissions for AdvSM and GIST on track for 1H 2026 and April 2026 respectively [6][7] - Clinical data from pivotal trials (SUMMIT, PEAK, APEX) will be presented at major medical meetings in 1H 2026 [6][7] Pipeline Expansion - Cogent is set to submit IND applications in 2026 for its pan-KRAS inhibitor and selective JAK2 V617F inhibitor, alongside ongoing studies for CGT4859 and CGT4255 [6][7][11] - The company is also establishing Expanded Access Programs for bezuclastinib to provide treatment options for eligible patients [5] Leadership and Organizational Changes - Abb Hayden has been appointed as Senior Vice President of Sales, bringing over 25 years of industry experience to the company [8] Presentation and Investor Engagement - Cogent will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, with a live webcast available for investors [9]